Early Access — free while we kick the tires
EdgarHawk

Hirsch Susan B

Director

Director

Latest: Director buying · April 2026

2 filings analyzed · 1 company · Latest 2026-04-14

Companies

Company Buys Sells Direction
TECOGEN INC. TGEN 2 0 Net buying

Activity

April 2026
2026-04-14 TECOGEN INC. TGEN
low
Buy
5,000 shares
$18,650
Significance 3/10

Director Susan B Hirsch buys 5,000 shares of TGEN at $3.73; second purchase in 17 days amid unprofitable operations.

Director Hirsch purchased 5,000 shares at $3.73, her second buy at TGEN within 17 days (prior buy on 2026-03-27), increasing her holdings to 265.4K shares. The stock is currently -68.6% from its 52-week high of $12.07 but up +37.3% over the past 30 days, suggesting some recent momentum. However, the company posted negative net income of -$2.1M in the latest quarter and was unprofitable over the full fiscal year, raising questions about the durability of near-term price gains. Hirsch's cross-ticker track record shows a 0.00% 90-day win rate on prior buys, and her only prior measurable buy at TGEN (2023-10-19) returned -12.6% over 90 days, indicating that her prior purchases at this ticker have not preceded sustained gains.

March 2026
2026-03-27 TECOGEN INC. TGEN
medium
Buy
10,000 shares
$25,400
Significance 4/10

Director Hirsch buys 10,000 TGEN shares at $2.54; stock down 78.7% from 52-week high amid unprofitable operations and -31.6% 30-day decline.

Director Susan B Hirsch purchased 10,000 shares of TECOGEN at $2.54 on 2026-03-27, increasing her holdings by 10,000 shares to 260,416 shares total. The purchase occurs against a backdrop of acute price deterioration: the stock trades at $2.57 current price, -78.7% from its 52-week high of $12.07 and down -31.6% over the prior 30 days. Fundamentally, the company reported a net loss of $-2,130,947.00 in its latest quarter and remains unprofitable on a full-year basis, though annual revenue growth reached +19.7%. Hirsch's prior open-market purchase at this ticker (2023-10-19) saw a -12.6% return over 90 days, establishing a pattern of ill-timed entry points; her cross-ticker track record shows 0 of 1 prior buys were well-timed at the 90-day mark. The transaction coincides with a cluster of 4 other insider buys within the past 14 days, though the broader context of sustained stock decline and negative profitability suggests this activity occurs amid material operational and valuation stress rather than as a signal of renewed confidence.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access